{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:04:25Z","timestamp":1793394265875,"version":"4.5.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.jtha.2024.07.009","type":"journal-article","created":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T21:20:07Z","timestamp":1721251207000},"page":"2889-2899","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":77,"title":["Reversal of direct oral anticoagulants: guidance from the SSC of the ISTH"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3766-4962","authenticated-orcid":false,"given":"Jerrold H.","family":"Levy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2405-7912","authenticated-orcid":false,"given":"Joseph R.","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1322-9368","authenticated-orcid":false,"given":"Lana A.","family":"Castellucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6445-582X","authenticated-orcid":false,"given":"Jean M.","family":"Connors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5288-0394","authenticated-orcid":false,"given":"James","family":"Douketis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edelgard","family":"Lindhoff-Last","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8304-6423","authenticated-orcid":false,"given":"Bianca","family":"Rocca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0460-6491","authenticated-orcid":false,"given":"Charles Marc","family":"Samama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3806-3245","authenticated-orcid":false,"given":"Deborah","family":"Siegal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1092-7550","authenticated-orcid":false,"given":"Jeffrey I.","family":"Weitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2024.07.009_bib1","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrcardio.2017.223","article-title":"Reversal agents for non-vitamin K antagonist oral anticoagulants","volume":"15","author":"Levy","year":"2018","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jtha.2024.07.009_bib2","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1502000","article-title":"Idarucizumab for dabigatran reversal","volume":"373","author":"Pollack","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.07.009_bib3","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1056\/NEJMoa1707278","article-title":"Idarucizumab for dabigatran reversal - full cohort analysis","volume":"377","author":"Pollack","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.07.009_bib4","doi-asserted-by":"crossref","first-page":"e204","DOI":"10.1097\/SLA.0000000000003638","article-title":"Dabigatran reversal with idarucizumab in patients requiring urgent surgery: a subanalysis of the RE-VERSE AD study","volume":"274","author":"Levy","year":"2021","journal-title":"Ann Surg"},{"key":"10.1016\/j.jtha.2024.07.009_bib5","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1056\/NEJMoa1510991","article-title":"Andexanet Alfa for the reversal of factor Xa inhibitor activity","volume":"373","author":"Siegal","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.07.009_bib6","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1182\/bloodadvances.2017007112","article-title":"Safety, pharmacokinetics, and reversal of apixaban anticoagulation with andexanet\u00a0alfa","volume":"1","author":"Siegal","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2024.07.009_bib7","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1056\/NEJMoa1814051","article-title":"Full study report of andexanet\u00a0alfa for bleeding associated with factor Xa inhibitors","volume":"380","author":"Connolly","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.07.009_bib8","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1161\/CIRCULATIONAHA.121.057844","article-title":"Final study report of andexanet\u00a0alfa for major bleeding with factor Xa inhibitors","volume":"147","author":"Milling","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2024.07.009_bib9","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jtha.2022.11.030","article-title":"Evaluation and management of oral anticoagulant bleeding: quid didicimus? (what have we learned?)","volume":"21","author":"Levy","year":"2023","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.07.009_bib10","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1056\/NEJMoa2313040","article-title":"Andexanet for factor Xa inhibitor-associated acute intracerebral hemorrhage","volume":"390","author":"Connolly","year":"2024","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.07.009_bib11","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1097\/ALN.0000000000002399","article-title":"Prothrombin complex concentrates for perioperative vitamin K antagonist and non-vitamin K anticoagulant reversal","volume":"129","author":"Levy","year":"2018","journal-title":"Anesthesiology"},{"key":"10.1016\/j.jtha.2024.07.009_bib12","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jtha.2022.11.029","article-title":"DOAC-associated bleeding, hemostatic strategies, and thrombin generation assays - a review of the literature","volume":"21","author":"Shaw","year":"2023","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.07.009_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.100107","article-title":"Four-factor prothrombin complex concentrate for the treatment of oral factor Xa inhibitor-associated bleeding: a meta-analysis of fixed versus variable dosing","volume":"7","author":"Chiasakul","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.07.009_bib14","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1002\/rth2.12418","article-title":"Andexanet versus prothrombin complex concentrates: differences in reversal of factor Xa inhibitors in in\u00a0vitro thrombin generation","volume":"4","author":"Lu","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.07.009_bib15","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/jth.13894","article-title":"Rivaroxaban reversal with prothrombin complex concentrate or tranexamic acid in healthy volunteers","volume":"16","author":"Levy","year":"2018","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.07.009_bib16","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1182\/bloodadvances.2018024133","article-title":"Management of direct factor Xa inhibitor-related major bleeding with prothrombin complex concentrate: a meta-analysis","volume":"3","author":"Piran","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2024.07.009_bib17","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1007\/s11239-021-02480-w","article-title":"Prothrombin complex concentrate in major bleeding associated with DOACs; an updated systematic review and meta-analysis","volume":"52","author":"Milioglou","year":"2021","journal-title":"J\u00a0Thromb Thrombolysis"},{"key":"10.1016\/j.jtha.2024.07.009_bib18","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s11239-018-1645-y","article-title":"Prothrombin complex concentrate for reversal of direct factor Xa inhibitors prior to emergency surgery or invasive procedure: a retrospective study","volume":"45","author":"Piran","year":"2018","journal-title":"J\u00a0Thromb Thrombolysis"},{"key":"10.1016\/j.jtha.2024.07.009_bib19","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1159\/000502173","article-title":"Prothrombin complex concentrate before urgent surgery in patients treated with rivaroxaban and apixaban","volume":"143","author":"Barzilai","year":"2020","journal-title":"Acta Haematol"},{"key":"10.1016\/j.jtha.2024.07.009_bib20","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.thromres.2020.06.044","article-title":"Activated prothrombin complex concentrates for direct oral anticoagulant-associated bleeding or urgent surgery: hemostatic and thrombotic outcomes","volume":"195","author":"Shaw","year":"2020","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2024.07.009_bib21","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1016\/j.jacc.2021.04.061","article-title":"Meta-analysis of reversal agents for severe bleeding associated with direct oral anticoagulants","volume":"77","author":"G\u00f3mez-Outes","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jtha.2024.07.009_bib22","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.40145","article-title":"Evaluation of direct oral anticoagulant reversal agents in intracranial hemorrhage: a systematic review and meta-analysis","volume":"5","author":"Chaudhary","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jtha.2024.07.009_bib23","article-title":"Lower mortality with andexanet\u00a0alfa vs 4-factor prothrombin complex concentrate for factor Xa inhibitor-related major bleeding in a U.S. hospital-based observational study","volume":"7","author":"Dobesh","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.07.009_bib24","article-title":"Thirty-day mortality with andexanet\u00a0alfa compared with prothrombin complex concentrate therapy for life-threatening direct oral anticoagulant-related bleeding","volume":"3","author":"Cohen","year":"2022","journal-title":"J\u00a0Am Coll Emerg Physicians Open"},{"key":"10.1016\/j.jtha.2024.07.009_bib25","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s11239-023-02820-y","article-title":"Real-world clinical outcomes among US veterans with oral factor xa inhibitor-related major bleeding treated with andexanet\u00a0alfa or 4-factor prothrombin complex concentrate","volume":"56","author":"Sutton","year":"2023","journal-title":"J\u00a0Thromb Thrombolysis"},{"key":"10.1016\/j.jtha.2024.07.009_bib26","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s13054-022-04043-8","article-title":"Andexanet\u00a0alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis","volume":"26","author":"Costa","year":"2022","journal-title":"Crit Care"},{"key":"10.1016\/j.jtha.2024.07.009_bib27","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.54916","article-title":"Prothrombin complex concentrate vs conservative management in ICH associated with direct oral anticoagulants","volume":"7","author":"Ip","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jtha.2024.07.009_bib28","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2217\/fca-2020-0073","article-title":"Real-world management of oral factor Xa inhibitor-related bleeds with reversal or replacement agents including andexanet\u00a0alfa and four-factor prothrombin complex concentrate: a multicenter study","volume":"17","author":"Coleman","year":"2021","journal-title":"Future Cardiol"},{"key":"10.1016\/j.jtha.2024.07.009_bib31","doi-asserted-by":"crossref","first-page":"e229","DOI":"10.1055\/s-0043-1771300","article-title":"Effect of PCC on thrombin generation among patients on factor Xa inhibitors with major bleeding or needing urgent surgery (GAUGE): design and rationale","volume":"7","author":"Shaw","year":"2023","journal-title":"TH Open"},{"key":"10.1016\/j.jtha.2024.07.009_bib33","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1160\/TH16-03-0224","article-title":"Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban","volume":"117","author":"Ansell","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.07.009_bib34","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.thromres.2016.07.008","article-title":"Ciraparantag safely and completely reverses the anticoagulant effects of low molecular weight heparin","volume":"146","author":"Ansell","year":"2016","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2024.07.009_bib35","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1093\/eurheartj\/ehab637","article-title":"Ciraparantag reverses the anticoagulant activity of apixaban and rivaroxaban in healthy elderly subjects","volume":"43","author":"Ansell","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jtha.2024.07.009_bib37","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/s41467-017-00647-9","article-title":"Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors","volume":"8","author":"Verhoef","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtha.2024.07.009_bib39","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1093\/ehjcvp\/pvac036","article-title":"Antithrombotic drug removal from whole blood using haemoadsorption with a porous polymer bead sorbent","volume":"8","author":"Tripathi","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.jtha.2024.07.009_bib40","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s40262-016-0417-0","article-title":"Effect of age and renal function on idarucizumab pharmacokinetics and idarucizumab-mediated reversal of dabigatran anticoagulant activity in a randomized, double-blind, crossover phase Ib study","volume":"56","author":"Glund","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jtha.2024.07.009_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0293632","article-title":"Thrombin generation, bleeding and hemostasis in humans: protocol for a scoping review of the literature","volume":"18","author":"Shaw","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.jtha.2024.07.009_bib42","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1161\/CIRCULATIONAHA.113.002283","article-title":"Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study","volume":"128","author":"Sarode","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2024.07.009_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.102175","article-title":"Toward non-factor therapy in hemophilia: an antithrombin insensitive Gla-domainless factor Xa as tissue factor pathway inhibitor bait","volume":"7","author":"Dagher","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.07.009_bib44","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1161\/ATVBAHA.123.318781","article-title":"New therapeutic targets for the prevention and treatment of venous thromboembolism with a focus on factor XI inhibitors","volume":"43","author":"Chan","year":"2023","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jtha.2024.07.009_bib45","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/jth.15579","article-title":"A\u00a0proposal for managing bleeding in patients on therapeutic factor XI(a) inhibitors","volume":"20","author":"Salomon","year":"2022","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.07.009_bib46","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1016\/j.ajem.2020.05.086","article-title":"A\u00a0review of guidelines on anticoagulation reversal across different clinical scenarios - is there a general consensus?","volume":"38","author":"Milling","year":"2020","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.jtha.2024.07.009_bib47","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1002\/rth2.12320","volume":"4","author":"Levy","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.07.009_bib48","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1160\/TH09-11-0758","article-title":"Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity","volume":"103","author":"van Ryn","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.07.009_bib49","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.thromres.2017.05.024","article-title":"Heparin-calibrated chromogenic anti-Xa assays are not suitable to assess the presence of significant direct factor Xa inhibitors levels","volume":"156","author":"Sabor","year":"2017","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2024.07.009_bib50","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1111\/bjh.17470","article-title":"A\u00a0universal anti-Xa assay for rivaroxaban, apixaban, and edoxaban measurements: method validation, diagnostic accuracy and external validation","volume":"193","author":"Willekens","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2024.07.009_bib51","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1001\/jamainternmed.2019.2431","article-title":"Perioperative management of patients with atrial fibrillation receiving a direct oral anticoagulant","volume":"179","author":"Douketis","year":"2019","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jtha.2024.07.009_bib52","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.thromres.2016.01.004","article-title":"Urgent surgery or procedures in patients taking dabigatran or warfarin: analysis of perioperative outcomes from the RE-LY trial","volume":"139","author":"Douketis","year":"2016","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2024.07.009_bib53","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/ijlh.13591","article-title":"Measuring residual anti-Xa activity of direct factor Xa inhibitors after reversal with andexanet\u00a0alfa","volume":"43","author":"Bourdin","year":"2021","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.jtha.2024.07.009_bib54","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11739-021-02866-x","article-title":"Perioperative management of antithrombotic therapy: a case-based narrative review","volume":"17","author":"Chen","year":"2022","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.jtha.2024.07.009_bib55","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/S0140-6736(20)31367-2","article-title":"Accelerated surgery for hip fractures-the HIP ATTACK results discussed \u2013 authors\u2019 reply","volume":"396","author":"Borges","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2024.07.009_bib56","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1055\/a-1549-6556","article-title":"Pharmacokinetics of direct oral anticoagulants in emergency situations: results of the prospective observational RADOA-Registry","volume":"122","author":"Lindhoff-Last","year":"2022","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.07.009_bib57","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1001\/jamaneurol.2024.0221","article-title":"Time to anticoagulation reversal and outcomes after intracerebral hemorrhage","volume":"81","author":"Sheth","year":"2024","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.jtha.2024.07.009_bib58","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1161\/STROKEAHA.123.043033","article-title":"Code ICH: a call to action","volume":"55","author":"Li","year":"2024","journal-title":"Stroke"},{"key":"10.1016\/j.jtha.2024.07.009_bib59","doi-asserted-by":"crossref","first-page":"e209","DOI":"10.1055\/a-2306-0804","article-title":"Clinical pathways and outcomes of andexanet\u00a0alfa administration for the reversal of critical bleeding in patients on oral direct factor Xa inhibitors","volume":"8","author":"Goldin","year":"2024","journal-title":"TH Open"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783624004264?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783624004264?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T20:46:25Z","timestamp":1759351585000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783624004264"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":54,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S1538783624004264"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2024.07.009","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reversal of direct oral anticoagulants: guidance from the SSC of the ISTH","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2024.07.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}